

A systematic review of rescue analgesic strategies in acute exacerbations of primary trigeminal neuralgia

D. Moore¹, M. S. Chong², A. Shetty² and J. M. Zakrzewska^{2,*}

¹Department of Anaesthesia, Beaumont Hospital, Dublin, Ireland and ²University College London Hospital, London, UK

*Corresponding author. E-mail: j.zakrzewska@ucl.ac.uk

Abstract

Background: Trigeminal neuralgia (TN) can have a significant impact on wellbeing and quality of life. Limited data exist for treatments that improve TN pain acutely, within 24 h of administration. This systematic review aims to identify effective treatments that acutely relieve TN exacerbations.

Methods: We searched Medline and Cochrane Central Register of Controlled Trials (CENTRAL) for relevant English language publications. The reference list for all articles was searched for other relevant publications. All studies that satisfied the following PICO criteria were included: (i) Population—adults with acute exacerbation of primary TN symptoms; (ii) Intervention—any medication or intervention with the primary goal of pain relief within 24 h; (iii) Comparator—usual medical care, placebo, sham or active treatment; (iv) Outcome—more than 50% reduction in pain intensity within 24 h of administration.

Results: Of 431 studies, 17 studies were identified that reported immediate results of acute treatment in TN. The evidence suggests that the following interventions may be beneficial: local anaesthetic, mainly lidocaine (ophthalmic, nasal or oral mucosa, trigger point injection, i.v. infusion, nerve block); anticonvulsant, phenytoin or fosphenytoin (i.v. infusion); serotonin agonist, sumatriptan (s.c. injection, nasal). Other referenced interventions with very limited evidence include N-methyl-D-aspartate receptor antagonist (magnesium sulphate infusion) and botulinum toxin (trigger point injection).

Conclusions: Several treatment options exist that may provide fast and safe relief of TN. Future studies should report on outcomes within 24 h to improve knowledge of the acute analgesic TN treatments.

Keywords: acute pain; anticonvulsant; drug therapy; humans; local anaesthetic; serotonin agonist; treatment outcome; trigeminal neuralgia

Editor's key points

- Patients with trigeminal neuralgia may suffer sudden, severe exacerbations of their pain. Emergency treatment has often consisted of opioid analgesics, which have no useful impact.
- The authors conducted a systematic review to determine how the symptoms of acute flare-ups of trigeminal neuralgia can be rapidly and effectively treated.

- There have been few RCTs, and those that have been performed are of variable quality. Current recommendations include the use of topical, injected or i.v. lidocaine, i.v. fosphenytoin, and topical or injected sumatriptan to abort an acute attack and improve the effectiveness of oral anticonvulsants.

Editorial decision: 03 May 2019; Accepted: 3 May 2019

© 2019 British Journal of Anaesthesia. Published by Elsevier Ltd. All rights reserved.
For Permissions, please email: permissions@elsevier.com

Trigeminal neuralgia (TN) is a painful condition that is associated with sudden, lancinating, unilateral pain attacks in the distribution of the trigeminal nerve branches. The attacks last from a few seconds up to 2 min and are often associated with typical triggers (e.g. brushing teeth, talking, eating). There is generally no pain between attacks.¹ Primary or classical TN can be attributable to compression of the trigeminal nerve by a blood vessel. Secondary TN is attributable to compression by a tumour or as a result of demyelination of the nerve (e.g. multiple sclerosis).²

The annual incidence of TN is reported as 4.7–28.9 per 100 000 person years.^{3,4} The age of onset is 53–60 yr and it is 1.5–1.9 times more common in women.^{5,6} TN can be a disabling condition and many patients often report moderate to severe episodes of pain with associated functional, occupational, and emotional impairment and disability.⁷ In a study by Tolle and colleagues⁸ of TN patients established on pharmacological treatment, 48% reported severe episodes of pain over a 24 h period and 78% report at least one visit to their primary care physician over a 4 week period. These patients missed on average 3.9 working days per month because of pain and 34% had reduced hours or were unemployed because of the pain.⁸

Most treatment options in TN are symptomatic and aim to reduce the severity and frequency of attacks in the

future. There is limited evidence on interventions that offer rescue analgesia in the acute phase of an exacerbation or attack. First line treatment is carbamazepine or oxcarbazepine.⁹ This is a very effective treatment option with large numbers reporting pain relief on initiation of treatment (98%).⁵ However, it is associated with many side-effects that limit its tolerability and 27% may have to stop or reduce the drug dose.⁵ Also, they must be titrated to effective concentrations over the course of days to weeks to avoid serious side-effects, making them ineffective as acute analgesics.

If pharmacological therapy fails or is not tolerated, interventional options include Gasserian ganglion rhizotomy and microvascular decompression. Such interventional options require image guidance, skilled staff, operating theatre access, or all three, which limits their utility as rescue options in the acute phase.

Data from Hospital Episodes Statistics in England show that not all patients admitted to hospital with acute TN undergo a surgical procedure. Patients in the UK and USA report the prevalent use of opioid analgesics from which it is inferred that the pain intensity is high.^{7,10} The management of these cases is challenging and can have serious socioeconomic and healthcare utilisation implications, not to mention the negative impact on the patient.




Fig. 1. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) flow diagram details the literature search. Of 452 potentially relevant studies, 17 studies investigated or referenced the efficacy of an analgesic therapy within 24 h of administration for trigeminal neuralgia. TN, trigeminal neuralgia.

The objective of our systematic review is to identify therapeutic strategies or interventions that effectively reduce the severity or terminate an acute exacerbation of TN. We will grade the evidence and offer recommendations that will support the care of these patients in the outpatient clinic, emergency department, or in the primary care setting.

Methods

Our review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.¹¹ We used a PICO approach to define our study inclusion criteria. The *Population* of interest was adults (>18 yr old) with primary TN as per the International Classification of Headache Disorders (ICHD 2013), International Association for the Study of Pain (IASP) definition, or both, with an acute exacerbation of symptoms.^{1,12} The *Intervention* was the administration of any medication or interventional treatment with the primary goal of acute pain relief within 24 h. The *Comparator* (or *control group*) may be usual medical care, placebo, sham, or active treatment. Because of the limited available evidence from RCTs, we reviewed all relevant studies (i.e. case reports, case series, observational studies, and RCTs). The primary *Outcome* measure we were interested in was pain intensity, and we deemed an effective treatment would give more than 50% pain relief within 24 h of administration. Other important outcomes we searched for included frequency of attacks, adverse effects of treatment, medication usage, healthcare utilisation, quality of life measures, and patient satisfaction scores.

Studies that reported on the use of interventions that require surgical theatre access or image guidance were excluded. Such interventions are not practical options in the pursuit of acute pain relief. Studies of medications that require days to weeks to titrate to effect were also excluded (e.g. carbamazepine, lamotrigine).

We performed a literature search for effective analgesic options in an acute TN exacerbation. We searched Medline and Cochrane Central Register of Controlled Trials (CENTRAL) for ('trigeminal neuralgia' OR 'facial/trigeminal nerve pain' OR 'tic do*lo*re*ux*') AND ('acute pain' OR 'emergency' OR

'refractory'). We only included full publications in English. The reference lists for all included papers were searched for other suitable papers. The literature was reviewed by two authors independently (DMM and JMZ) and agreement on study inclusion was sought. If there was a disagreement on study inclusion, a third author (MSC) made the final decision. A PRISMA flow diagram of our search results is included below (Fig 1).

After pooling the search results, we removed duplicates. We reviewed the abstracts and selected studies that may meet inclusion criteria. We retrieved the full article for these studies and extracted data for inclusion in the review. We graded the level of evidence using the American Academy of Neurology classification scheme (Table 1).¹³

We used the Cochrane Collaborations risk of bias tool to rate the level of bias in the included RCTs.¹⁴ As per the Cochrane group's recommendation, all other studies were deemed to be at 'high' risk of bias. Finally, we used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) summary of evidence tool to rate the quality of evidence and accordingly grade our recommendations.¹⁵

Results

A total of 17 studies met our inclusion criteria (Fig 1). All studies investigated the effect of a pharmacological intervention, and the results are detailed below under each drug group heading. Table 2 gives an overview of the interventions and the results from each study. Figure 2 indicates the level of bias in the included RCTs. Not all the drugs mentioned in this review are available in all countries.

Local anaesthetic

Ophthalmic

In 1992, a prospective observational study assessed the impact of proparacaine 0.5% eye drops on 25 patients.¹⁶ This study was inspired by a letter published by Zavan and Fichte¹⁷ that reported the unintended relief of TN in a patient presenting for cataract surgery and a second patient with symptoms resistant to carbamazepine, both of whom received proparacaine 0.5% eye drops. All participants in the


Table 1 American Academy of Neurology (AAN) classification scheme requirements for therapeutic questions (<https://www.aan.com/policy-and-guidelines/guidelines/about-guidelines2/>).

Class I	A randomised, controlled clinical trial of the intervention of interest with masked or objective outcome assessment, in a representative population. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.
Class II	A randomised controlled clinical trial of the intervention of interest in a representative population with masked or objective outcome assessment that lacks one criteria of the additional class 1 criteria or a prospective matched cohort study with masked or objective outcome assessment in a representative population that meets Class I criteria. Relevant baseline characteristics are presented and substantially equivalent among treatment groups or there is appropriate statistical adjustment for differences.
Class III	All other controlled trials (including well-defined natural history controls or patients serving as their own controls) in representative populations, where outcome is independently assessed, or independently derived by objective outcome measurement.
Class IV	Studies not meeting Class I, II, or III criteria including consensus or expert opinion.

Table 2 Evidence for acute analgesic treatments in trigeminal neuralgia. DN4, douleur neuropathique 4 questionnaire; GIC, global impression of change; IASP, International Association for the Study of Pain; ICHD, International Classification of Headache Disorders; IV, intravenous; MgSO₄, magnesium sulphate; N, number of study patients; NRS, numerical rating scale; PE, phenytoin equivalents; PRS, pain relief scale; RCT, randomised controlled trial; SC, subcutaneous; TN, trigeminal neuralgia; V2, second division of trigeminal nerve; V3, third division of trigeminal nerve; VAS, visual analogue scale; VPR, verbal pain rating.

Author (and year)	Drug	Study	Diagnosis	Population	N	Dosage
Zavon and Fichte ¹⁷ (1991)	Proparacaine	Case report	Not specified	Classical TN Presenting for cataract surgery	1	0.50%
Spaziante and colleagues ¹⁶ (1992)	Proparacaine	Prospective observational	Not specified	Classical TN All divisions	25	0.5% (2 drops)
Kanai and colleagues ¹⁹ (2006)	Lidocaine	RCT cross-over double-blind	ICHD	Classical TN Division: V2 Intensity on VAS>4/10	25	Active: 8% 0.2 ml, Control: 0.2 ml saline
Niki and colleagues ²⁰ (2014)	Lidocaine	RCT cross-over double-blind	ICHD	Classical TN Division: V2, V3 Intensity on VAS>4/10	24	Active: 8% 0.2 ml, Control: saline 0.2 ml
Baykal and Kaplan ²⁴ (2010)	Lidocaine	Retrospective observational	Not specified	Classical TN Division: V2, V3	13	5 ml 2% (100 mg)
Galer and colleagues ²¹ (1993)	Lidocaine	Retrospective observational	Not specified	TN with concomitant persistent facial pain	6	5 mg kg ⁻¹ h ⁻¹
Stavropoulou and colleagues ²³ (2014)	Lidocaine	RCT cross-over double-blind	IASP	Classical TN All divisions DN4 Score>4 VAS>3/10	20	5 mg kg ⁻¹
Chaudhry and Friedman ²² (2014)	Lidocaine	Case report	Not specified	TN with concomitant persistent facial pain Division: V2	1	60 mg h ⁻¹ for 4 h, 120mg h ⁻¹ for next 20 h, followed by 60 mg h ⁻¹ for next 48 h
Arai and colleagues ²⁶ (2013)	Lidocaine+magnesium sulphate	Retrospective observational	Not specified	Classical TN Division: V2	9	Lidocaine 100 mg and MgSO ₄ 1.2 g
Soleimanpour and colleagues ²⁵ (2014)	Magnesium sulphate	Case report	Not specified	Classical TN - acute presentation	1	50 mg kg ⁻¹
Tate and colleagues ²⁷ (2011)	Phenytoin	Case report	Not specified	Classical TN - acute presentation	1	15 mg kg ⁻¹
Cheshire ²⁹ (2001)	Fosphenytoin	Case series	Not specified	Classical TN - acute presentation, carbamazepine no longer effective	3	14 (11–18) mg kg ⁻¹ (PE) over 20–180 min
Vargas and Thomas ²⁸ (2015)	Fosphenytoin	Case report	Not specified	Classical TN - acute presentation Division: V2+V3	1	15 mg kg ⁻¹
Zuniga and colleagues ³⁴ (2008)	Botulinum toxin	Prospective observational	Not specified	Classical TN All divisions	12	20–50 units
Kanai ³⁰ (2006)	Sumatriptan	RCT cross-over double-blind	ICHD	Classical TN All divisions Intensity on VAS>4/10	24	Active: 3 mg (1 ml) Control: 1 ml saline
Kanai ³² (2006)	Sumatriptan	Prospective observational, placebo-controlled, partially blinded	ICHD	Classical TN All divisions	15	3 mg (1 ml) s.c. followed by 50 mg orally twice daily for 1 week
Shimohata and colleagues ³³ (2009)	Sumatriptan	Case series	ICHD	Classical TN All divisions	3	20 mg

Route	Outcome measure(s)	Efficacy within 24 h	Side-effects (n)	Level of evidence	Risk of bias
Eye drops	Incidental reduction of TN pain	Alleviation of pain	Not specified	IV	High
Eye drops	50% Reduction of analgesics	15 Patients > 50% reduction (8 stopped all analgesics)—not clear at which timepoint over a 1 month period	Nil	IV	High
Nasal spray	VAS (15 min post-intervention), GIC (4-point scale), use of medications	Active: VAS 8.0 to 1.5, Control: 7.9 to 7.6, Duration: 4.3 h	Local irritation (stinging, burning numbness) (15), bitter taste or numb throat (1)	II	Unclear
Oral mucosa (trigger point)—applied via patients finger	NRS, GIC (4-point scale)	Active: NRS 5 to 1, Control: 5 no (change), Duration: 2.8 h	Numbness (active [9], control [3]), bitterness (1)	II	Unclear
'Blind' injection of 2nd or 3rd division via mandibular notch	VAS	Complete relief 1–2 min post-injection	Hypoesthesia (4), dizziness (3), ptosis (1), insufficient block (1)	IV	High
I.V. infusion over 60–90 min	VPR, VAS, PRS 1 h post-infusion	5 Patients >70% reduction in VAS or VPR, 1 patient 30–70% reduction	Not specified	IV	High
I.V. infusion over 60 min	VAS, allodynia, hyperalgesia	VAS: (active) 76% reduction, (control) 40.1% reduction; at 24 h, (active) 52% reduction (control) 4% increase, decrease in evoked pain	Mild somnolence (33%), 3 patients dropped out	II	Low
I.V. infusion for 72 h	VPR	VPR: 10 to 0 after 1st h infusion	Not specified	IV	High
I.V. infusion over 60 min	NRS	NRS: 7 to 4	Mild dizziness (2)	IV	High
I.V. infusion over 30 min	VAS	VAS: 10 to 2 (30 min post-infusion)	Nil	IV	High
I.V. infusion in 2 divided doses 4 h apart	NRS	NRS: 10 to 2 after 1st infusion and 1 after 2nd infusion	Nil	IV	High
I.V. infusion	Pain relief (not quantified)	Immediate pain relief post-infusion	Mild and transient dizziness, tinnitus, ataxia	IV	High
I.V. infusion over 30 min	VAS	VAS: 10 to 2	Not specified	IV	High
S.C. trigger zones	VAS (8 weeks)	10 Patients: relief 'after some minutes', 1 patient: VAS 10 to 0 in 24 h	Transient facial asymmetry (1)	IV	High
S.C.	VAS (15 min post-intervention), GIC (4-point scale)	Active: Vas 8.3 to 2.4, Control: 8.5 to 8.1, Duration: 7.9 h	Mild hypertension (2), fatigue (5), nausea (2)	II	Unclear
S.C. saline, then s.c. sumatriptan, followed by oral 1 day later	VAS (15 min post-intervention)	VAS decreased by 4.0 (resting), 4.7 (touching face), 4.6 (talking)	Fatigue (4), nausea (2)	IV	High
Nasal spray	VAS	VAS: 8 to 2 (30 min)	Nil	IV	High



observational study were managed as TN cases, but the diagnostic criteria are not clear. Patients with incomplete pain relief on standard treatment or awaiting surgery were included. A positive outcome was more than 50% reduction in analgesic medications. This was reported in 15 of the 25 patients, with eight patients stopping all medications. Positive response was not limited to those with first division symptoms. The duration of follow-up was for ‘at least a month’, but the exact time frame for each patient was not documented. Also, the time to onset of pain relief in the 15 patients is not reported. No adverse events were reported.

A subsequent RCT in 47 patients with TN (primary and secondary cases) rejected the long-term benefit of proparacaine 0.5% eye drops.¹⁸ However, the first patient report was recorded at 3 days, so no acute pain reduction within the first 24 h was assessed.

Nasal

Kanai and colleagues¹⁹ published a double-blind cross-over RCT in 25 patients with second division TN. Patients were randomised to receive two sprays of lidocaine 8% (0.2 ml, 16 mg, $n=13$) or two sprays of saline solution (0.2 ml, $n=12$) in the ipsilateral nostril to the pain. After 7 days, the groups crossed over to receive the alternative treatment. Patients remained supine with their head in a neutral position for 30 min during observation, presumably to establish a sphenopalatine ganglion block.

The primary outcome was pain score (visual analogue scale [VAS]) on stimulation of a trigger zone. VAS in the lidocaine group reduced from 8.0 to 1.5, while the saline group reported a non-significant reduction from 7.9 to 7.6. Ten patients (40%) in the lidocaine group reported complete pain relief at 15 min. This positive effect of lidocaine persisted for a median of 4.3 h. Fifteen patients (60%) in the lidocaine group reported minor adverse side-effects which included stinging, burning, or numbness of the nose and eye ($n=15$), bitter taste, and numbness of the throat ($n=1$).

Oral

The same Japanese group as above conducted a study of lidocaine use in patients with primarily oral mucosa trigger points.²⁰ They used a similar methodology to the previous study.¹⁹ They recruited 24 patients with TN in the maxillary branches, mandibular branches, or both. A dose of lidocaine spray 8%, 2 ml was applied to the patients finger and rubbed into the trigger zone of the oral mucosa ($n=12$). Alternatively, the patient rubbed 0.2 ml of saline into the painful zone ($n=12$). The numeric rating scale (NRS) in the lidocaine group reduced from five down to one. NRS in the saline group did not change from five. Eleven patients (46%) were pain free after lidocaine application. Only one patient in the saline group reported complete pain relief. The median duration of pain relief was 2.8 h (0.3, 3) in the lidocaine group.

I.V. infusion

Galer and colleagues²¹ reported on the use of lidocaine infusions in the management of neuropathic pain in 111 patients in a retrospective cohort study. Six of these patients were diagnosed with TN. The patients described their pain as ‘near constant lancinating pain’ which may indicate that they had classical TN with concomitant persistent facial pain (Type 2 TN). The patients received lidocaine $5 \text{ mg kg}^{-1} \text{ h}^{-1}$ infusion for 60–90 min. At 1 h post-infusion, one patient reported partial relief (30–70% reduction in pain score) and five patients reported excellent relief (more than 70% reduction in pain scores). The authors did not mention adverse side-effects.

Chaudhry and Friedman²² reported a case of lidocaine infusion relieving intractable TN symptoms from a verbal pain rating of 10/10 down to 0/10 after the first hour of infusion. The patient was on an infusion over a 72-h period, running at 60–120 mg h^{-1} .

Stavropoulou and colleagues²³ designed a cross-over double-blind RCT to assess the role of lidocaine infusion in TN. The study included patients with TN as per IASP criteria, and only patients who had a Douleur Neuropathique 4 Questionnaire (DN4) score equal to or greater than 4 (out of a maximum 10). The majority of patients had hyperalgesia and allodynia (thermal and mechanical) on examination. Each patient received four infusions (each infusion 2 days apart), two active and two control, allocated at random. The active infusion was lidocaine 5 mg kg^{-1} in 250 ml of dextrose 5% solution given over 1 h. The control infusion was dextrose solution 5%, 250 ml. At 1 h post-infusion, the overall reduction in pain score (VAS) was 76.4% for the active group vs 40.1% for the control group. At 24 h, pain scores reduced by 52% for the active group vs a 4% increase in pain score for the control group. The active group also reported decreased hyperalgesia and allodynia. Somnolence was the most common side-effect reported in 33% of the active infusions.

Nerve block

Baykal and Kaplan²⁴ reported on the use of blind injection of the mandibular and maxillary branches of the trigeminal nerve at the level of the lateral pterygoid plate or the pterygopalatine fossa, respectively. Their study included 13 patients presenting with TN symptoms, the severity of which is not clearly documented. They performed a weekly injection with lidocaine 2%, 5 ml over a 5-week period (six injections). The patients were 'completely pain free in 1–2 min' post-injection. However, they did not report on baseline or post-intervention pain scores. They used this 5-week period to establish or titrate the carbamazepine dose. After this, one patient remained pain-free for 1 month, another two remained pain-free for 6 months, and the remaining 10 patients were pain-free for at least 12 months. Side-effects were hypoesthesia ($n=4$), dizziness ($n=3$), ptosis ($n=1$), and incomplete block ($n=1$).

N-Methyl-D-aspartate receptor antagonists

A case report details the use of a magnesium sulphate ($MgSO_4$) infusion to control an acute exacerbation of TN.²⁵ A 65-yr-old man presented to the emergency department with a VAS score of 10/10 and received $MgSO_4$ 30 mg kg^{-1} in 100 ml saline, infused over 30 min. His pain score decreased to 2/10 at 30 min post-infusion. He did not report any adverse effects. He was monitored for 4 h and was then discharged from the emergency department.

Arai and colleagues²⁶ retrospectively reported the outcomes of nine patients with TN intractable to conventional treatment who were treated with a combined infusion of lidocaine and $MgSO_4$. Each patient received lidocaine 100 mg mixed with $MgSO_4$ 1.2 g infused over 1 h. The mean NRS for the patients reduced from 7 down to 4 after the infusion. It is not clear how soon after the infusion the pain score was recorded. Two patients reported mild dizziness post-infusion.

Anticonvulsants

The i.v. anticonvulsants reported to be effective in the literature are phenytoin and its prodrug fosphenytoin. A case report of a 77-yr-old man with intractable TN supports the use of i.v. phenytoin.²⁷ After admission to the emergency department, he received a phenytoin infusion of 15 mg kg^{-1} in two divided doses each infused over 30 min. His pain score decreased from 10/10 down to 1/10 after the infusions. This pain relief persisted for up to 3 days. No adverse effects were reported. Vargas and Thomas²⁸ published a case report of a 53-yr-old man who presented to the emergency department with intractable TN symptoms. He received 15 mg kg^{-1} of fosphenytoin over 30 min. His pain score (VAS) reduced from 10/10 to 2/10 immediately after the infusion. No adverse effects were reported. The pain relief was maintained at follow-up 20 days later.

Cheshire²⁹ reports a case series of three patients with intractable TN who responded to a fosphenytoin infusion. All three patients were previously controlled on carbamazepine, but subsequently developed an acute, unremitting phase of TN attacks that compromised their ability to eat or drink. The fosphenytoin was diluted to phenytoin sodium equivalents (PE) 5–10 mg ml^{-1} in dextrose 5% with saline 0.45%. During infusion, the patients were monitored with ECG and noninvasive BP observations. The first patient received PE of fosphenytoin 18 mg kg^{-1} over 20 min. This gave immediate pain relief which lasted 2 days. She opted for an microvascular

decompression (MVD). The second and third patients received an incremental dosing schedule of 100 mg every 10 min up to a maximum of 10 doses in order to limit the required dose. Patient 2 received good pain relief after an 11 mg kg^{-1} dose, and this was maintained for 20 h. The patient subsequently had a trigeminal ganglion balloon compression. The third patient had 14 mg kg^{-1} infused in increments as above over 3 h, with immediate pain relief. This lasted for 2 days. This patient also opted for trigeminal ganglion balloon compression. All patients reported transient adverse effects including mild dizziness, tinnitus, and ataxia.

Serotonin agonists

Kanai and colleagues³⁰ reported on the use of s.c. sumatriptan in triggered TN attacks. They used a similar methodology to the previously mentioned studies.^{19,20,31} Patients received either s.c. sumatriptan 3 mg in 1 ml ($n=12$) or s.c. saline 1 ml ($n=12$). Sumatriptan decreased VAS from 8.3 down to 2.4. There was no significant decrease in the saline group with 8.5 down to 8.1. Twelve patients (50%) were pain free after sumatriptan. The positive effect of sumatriptan lasted for a median of 7.9 h (range of 1–20 h). The reported adverse effects in the sumatriptan group included mild elevation in BP ($n=2$), fatigue ($n=5$), and nausea ($n=2$).

A further study by the same group in patients ($n=15$) with at least a 1 month exacerbation of TN symptoms demonstrated a significant decrease in VAS pain scores while resting (4.0), touching (4.7), and talking (4.6) in those who received s.c. sumatriptan (3 mg in 1 ml).³² They maintained these positive improvements with a 1 week course of oral sumatriptan 50 mg twice daily.

Nasal sumatriptan (20 mg) was effective in a case series of three patients with refractory TN reducing the mean VAS from 8 to 2 within 30 min.³³ No adverse effects were reported.

Botulinum toxin

Zuniga and colleagues³⁴ reported on the use of botulinum toxin injections in the trigger zones of patients with primary TN. The 12 patients were assessed weekly for 8 weeks in an open label study. The patients received 20–50 units in total to individual trigger points. The authors reported that 10 of the patients (83%) experienced pain relief 'after some minutes' of the injection. They also noted faster onset of pain relief with higher doses. However, precise details about pain scores or number of paroxysms within the first 24 h are not reported. They give details of one female patient who had a pain score (VAS) of 10 and 30–40 painful paroxysms per day. She received 40 units into a left frontotemporal trigger point, and five units each into a zygomatic and buccal trigger point. At 24 h, her pain score was 0 and she had no painful paroxysms. This level of pain relief persisted for 70 days. The same group published an RCT on botulinum toxin in primary TN.³⁵ In the article, they refer to unpublished observations of TN pain that 'almost remitted at the time of injection'. Other reports on botulinum toxin use in TN do not record the acute response.

Discussion

Quality of evidence

The overall quality of evidence for effective acute analgesia in TN exacerbations is very low. A number of reasons may exist

for this. TN is a rare condition and the number of patients required to adequately power an RCT makes such a project very difficult. Also, the majority of TN patients respond well to conventional treatment with carbamazepine. The patient group of interest in this review is a small subset of TN patients. TN is associated with painful paroxysms that may remit for long periods of time. In observational studies it can be difficult to determine if the remission is because of treatment or simply the natural course of the condition. As such, the review includes small RCTs, observational studies, and case series/reports. In addition, many of the included studies did not specifically look at acute (emergency department or outpatient clinic) presentations, and some specifically triggered attacks to judge the acute effect of treatment,^{19,20,30,32} while others included patients with intractable symptoms with conventional management.^{16,18,26,34} However, all included studies reported on the degree of acute relief of TN pain within 24 h.

Very few studies in TN report outcomes within the first 24 h of starting treatment. The earliest timepoint in many studies was 7 days post-intervention, and so these were excluded. While the ultimate goal of therapy should be to reduce the intensity and frequency of TN attacks, patients would also value a therapeutic strategy that provides a fast resolution of symptoms.

Local anaesthetic

The primary agent used in the included trials was lidocaine. Like all local anaesthetic agents, it is a voltage-gated sodium channel blocker and its effect in TN is most likely attributable to its inhibition of the triggering mechanism in the ignition hypothesis, proposed by Devor and colleagues.³⁶ Its therapeutic effect in the trials that involved local application (e.g. nasal or oral mucosa) is certainly because of blockade of the peripheral nerve sodium channels. In higher systemic doses, it can demonstrate a neuromodulatory effect by reducing C-fibre transduction of pain signals and inhibition of ectopic discharges from damaged neurons, without impacting on normal sensory function.^{37,38} This would account for its effect in the i.v. infusion studies. While it has a shorter duration of action than other local anaesthetics, it is preferred because of its better safety profile in terms of cardiac and neurological toxicity.

The effect of proparacaine 0.5% eye drops in TN is equivocal. It may have an effect that is lost after a few hours, but further studies are required to establish this. This is the case in nasal and oral mucosal lidocaine which gave a median of 4.3 and 2.8 h of pain relief, respectively. The method of application used in applying the lidocaine to the oral mucosa (spray on the patients' finger) was unusual,²⁰ and in patients with mucosal trigger zones, it could be sprayed directly but using a lower concentration (e.g. 5%).

Studies investigating the effects of i.v. lidocaine included primarily TN patients with concomitant persistent facial pain (Type 2 TN). The dose of 5 mg kg⁻¹ infused over 1 h is recognised to be effective and safe in other neuropathic pain states.³⁹ The study by Stavropoulou and colleagues²³ used the DN4 (score >4) to select patients with trigeminal neuropathic pain. However, the DN4 is not specific enough for TN and may actually select outpatients with concomitant persistent facial pain (Type 2 TN).⁴⁰ As such, the role of i.v. lidocaine in classical primary TN (Type 1) is not clear. Matharu and colleagues⁴¹ reported on the use of lidocaine infusions (1.3–3.3 mg kg⁻¹ h⁻¹) in short-lasting unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT), considered by some as TN with autonomic features. The SUNCT symptoms

were significantly relieved by the infusion, but recurred soon after discontinuation.

A number of studies have investigated the utility of trigger point or distal nerve branch injection of local anaesthetic in TN patients. These included continuous infusion of bupivacaine around the peripheral nerve branches,⁴² ropivacaine to trigeminal trigger points either alone or in combination with gabapentin,⁴³ peripheral nerve injection of lidocaine vs streptomycin plus lidocaine,^{44,45} peripheral and proximal nerve blocks with high concentration lidocaine,⁴⁶ and tetracaine with or without bupivacaine peripheral nerve injection.^{47,48} While these trials reported variable long-term outcomes, none of them reported acute outcomes within the first 24 h. The Baykal paper reported on the use of more proximal nerve blocks to achieve acute pain relief while titrating carbamazepine.²⁴ These blocks should be done with image-guidance and contrast screening for vascular uptake.

Local anaesthetic injection to trigger points offers effective but transient relief of symptoms (less than 24 h). Indeed, all the local anaesthetic interventions included in this review have a limited duration of action (2–24 h). However, this may be valuable to the patient during a period of drug titration or waiting for a more definitive treatment to be established. Importantly, the risk profile of the interventions is low, as is the cost of the medications used. Many can be performed by dental practitioners who in the UK use lidocaine 1–2%. Lidocaine infusions, on the other hand, require a nurse monitored bed for the duration of the infusion which adds to the treatment cost.

N-Methyl-D-aspartate receptor antagonists

N-Methyl-D-aspartate (NMDA) receptor activation is a key step in central sensitisation and NMDA antagonists may improve the associated symptoms.⁴⁹ Central sensitisation is not believed to be a significant part of classical TN.³⁶ The typical clinical features of central sensitisation are allodynia and hyperalgesia. These may be observed in trigeminal neuropathies, Type 2 TN, or persistent idiopathic facial pain, but should not be present in classic primary TN.

MgSO₄ is a natural NMDA receptor blocker and a magnesium ion resides in the receptors central pore in normal physiological states. During periods of intense nociceptive input, the Mg ion is displaced, and the NMDA receptor can facilitate calcium influx, potentiating the nociceptive signal at the dorsal horn level in the spinal cord—one element of central sensitisation.

The included case report and case series offer very weak evidence for the use of MgSO₄ in managing the acute pain of TN. In the case series, the nine patients received lidocaine 100 mg (less than 2 mg kg⁻¹) combined with MgSO₄ 1.2 g (approximately 20 mg kg⁻¹ over 1 h). The case report dose was 30 mg kg⁻¹ infused over 30 min. The advantage of MgSO₄ infusion is that it is cheap with minimal side-effects. It has proven efficacy in the management of other neuropathic pain conditions such as post-herpetic neuralgia and neuropathic back and leg pain.^{50,51}

Other NMDA receptor blockers have been trialled in small case series of facial pain patients. Patients with chronic facial pain received various sub-anaesthetic doses of ketamine.⁵² Of the seven patients, only three reported transient pain relief (1–3 days) with doses of 0.4–1.8 mg kg⁻¹ of ketamine. All patients had pain secondary to traumatic trigeminal nerve injury rather than TN. A study of dextromethorphan (NMDA antagonist) in facial neuralgias included three patients with primary TN.⁵³




Fig. 3. Evidence-based treatment algorithm for the management of acute exacerbations of trigeminal neuralgia. Management of acute exacerbations should proceed in parallel with a more definitive long-term management plan. The quality of evidence is included after each intervention. The moderate- and high-quality evidence receives a 'should consider' recommendation. The very low- and low-quality evidence are options that the clinician 'may consider' if interventions with higher quality evidence are contraindicated or not available. *Sumatriptan injection pens in the UK contain 6 mg in 1 ml, and we have recommended this for convenience as opposed to the 3 mg used by the Japanese group. [†]These concentrations may not be available in all countries (2–5% more common). TN, trigeminal neuralgia.

While acute pain relief was not reported, the patients' pain control over a 14-day period was worse on the oral dextromethorphan compared with oral lorazepam (active control).

Anticonvulsants

Treatment algorithms for TN contain many anticonvulsant agents including carbamazepine, oxcarbazepine, lamotrigine, and gabapentin.^{9,54} However, many of these agents are not available in i.v. form and their oral administration requires a period of cautious titration. This makes them unsuitable for the management of acute TN attacks.

The exception to the above is phenytoin, or its prodrug fosphenytoin, which is a commonly used i.v. anticonvulsant.

Both drugs have been used successfully in the acute control of TN attacks. The evidence is weak, based on case reports and a small case series. Phenytoin is a use-dependent antagonist of voltage-gated sodium channels. It selectively blocks sodium channels that are opened repeatedly, a property which makes it an effective anticonvulsant.⁵⁵ It also blocks voltage-gated calcium channels. These pharmacodynamic properties help to explain how it may inhibit the triggering and amplification steps in the ignition hypothesis. Fosphenytoin is a phenytoin prodrug with a better side-effect profile.⁵⁶ The loading dose for both drugs is 15–18 mg kg⁻¹ over 30 min. Similar to lidocaine infusions, the patient requires a nurse-monitored bed during the infusion. Adverse effects include dizziness and ataxia, hypotension, and rarely heart block.

The onset of pain relief in the included cases was immediate post-infusion and lasted for 1–3 days on average. This allowed the patients to consider more definitive treatment options.

Serotonin agonists

Sumatriptan is the most commonly used triptan and is a serotonin (5-hydroxytryptamine) agonist, specifically serotonin 1B and 1D receptors.⁵⁷ It may be administered orally, intranasally, s.c., or rectally. It is a first line rescue agent in migraine treatment, and it is most effective when given s.c. at a dose of 6 mg.⁵⁸ It may also have a role in the acute management of TN attacks.

Its mechanism of action in the termination of migraine attacks is believed to be direct vasoconstriction of dilated meningeal blood vessels, inhibition of release of vasodilatory peptides from trigeminal sensory neurons, and a reduction in pain transmission in the trigeminal dorsal horn in the pons.^{59–61} Sumatriptan may exert its analgesic effect in TN by reducing pain transmission in the pons. As a vasoconstrictor, it may also reduce the mechanical compression of the trigeminal nerve root by a vascular loop.

While the use of the s.c. route is more effective in migraine management, and was the chosen route in the included studies, it is more expensive than the oral option. The nasal route is a more attractive option in a patient with acute TN symptoms who cannot take oral medication or wants to avoid injections. Sumatriptan is generally well tolerated but may be associated with moderate increases in BP. It should be used with caution in hypertensive patients or those with coronary artery disease.

Botulinum toxin

Botulinum toxin is indicated as a prophylactic treatment in the management of refractory chronic migraine,^{62,63} and a growing number of observational and RCT studies support its use in refractory primary TN.⁶⁴ However, there is limited data on its acute analgesic effect. The included studies were not designed to investigate the acute analgesic effect of botulinum toxin in this patient group, but remark on the early onset of pain relief.

The mechanism of action of botulinum toxin in painful conditions such as chronic migraine or TN is believed to be inhibition of neuropeptide release (e.g. calcitonin gene-related peptide and substance P) from peripheral sensory nerve endings.⁶⁵ This may limit peripheral sensitisation and could account for a role in reducing neural triggering in TN. However, in comparison with other treatment options, botulinum toxin is more expensive, with the National Institute of Health and Care Excellence estimating each treatment for chronic migraine may cost £349.40. A mixture of botulinum toxin and lidocaine into trigger points to manage acute exacerbations in specific cases could be trialled. The botulinum toxin prolongs the acute effect of the lidocaine, and we have had a number of positive results with this approach. As such, while the evidence is still weak for acute exacerbations, a case-by-case basis could be considered in experienced specialist centres.

Algorithm for acute management

If a patient presents with an acute exacerbation of their facial pain, it is important to confirm that this is consistent with primary TN.⁶⁶ If the pain is different in quality or character to their usual TN pain, or if they report red-flag symptoms, a

clinical history, examination with or without investigations are warranted to rule out a secondary cause.

However, if the patient has a diagnosis of primary TN and this episode is consistent with previous attacks, then it is appropriate to treat without further investigations. The GRADE summary of evidence table gives an indication of how the data was graded ([Supplementary Table S1](#)). It is recommended to start with the intervention with the highest evidence, and lowest cost and side-effects ([Fig 3](#)). Most of the interventions are associated with immediate relief (within 1 h of completing the therapy). Therefore, it is appropriate to move swiftly through the algorithm if a treatment has not been successful.

Most of the interventions give less than 24 h of pain relief, so a more definitive care plan needs to be put in place according to current guidelines.^{9,67} This may involve starting or titrating medications, or planning surgical interventions. The case series by Cheshire²⁹ describes this process well with the acute management of three patients with fosphenytoin infusion while simultaneously planning more definitive management plans. Some of the studies count the early discontinuation or reduction of prophylactic medications (e.g. carbamazepine) as a positive outcome measure, and the Japanese studies even discontinued these medications 12 h before intervention.^{19,20,30} Abrupt discontinuation of a well-tolerated medication is not generally recommended and in an acute exacerbation, increasing the dose of these medications to achieve better long term control is the preferred option.

Conclusion

Trigeminal neuralgia is associated with periods of moderate to severe flare-up that can have a detrimental impact on an individual's personal and professional life. Many current treatment strategies are aimed at long-term symptom control and fail to give acute pain control (within 24 h). This may lead to work absence or hospital admission. Weak evidence exists to support the use of lidocaine, sumatriptan, phenytoin/fosphenytoin, botulinum toxin, and MgSO₄ as acute rescue analgesics. Future studies of interventions in TN should consider recording the first point of onset of analgesia and the duration of effect. It may be necessary to look at N-of-one trials to get over some of the difficulties of designing RCTs of acute management.

Authors' contributions

Systematic literature search and review, study inclusion, data extraction: DMM, JMZ.

Manuscript preparation and revision: all authors.

Data retrieval: MSC, AS.

Adjudication on study inclusion: MSC.

Declaration of interest

JMZ has a consultancy with Biogen.

Funding

JMZ undertook this work at University College London and University College London Hospital Trust, UK who received a proportion of funding from the Department of Health's National Institute for Health Research (NIHR), UK Biomedical Research Centre funding scheme.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.bja.2019.05.026>.

References

- Olesen J. International classification of headache Disorders. *Lancet Neurol* 2018; **17**: 396–7
- Cruccu G, Finnerup NB, Jensen TS, et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. *Neurology* 2016; **87**: 1–9
- Hall GC, Carroll D, McQuay HJ. Primary care incidence and treatment of four neuropathic pain conditions: a descriptive study, 2002–2005. *BMC Fam Pract* 2008; **9**: 26
- Koopman JS, Dieleman JP, Huygen FJ, de Mos M, Martin CG, Sturkenboom MC. Incidence of facial pain in the general population. *Pain* 2009; **147**: 122–7
- Di Stefano G, La Cesa S, Truini A, Cruccu G. Natural history and outcome of 200 outpatients with classical trigeminal neuralgia treated with carbamazepine or oxcarbazepine in a tertiary centre for neuropathic pain. *J Headache Pain* 2014; **15**: 34
- Maarbjerg S, Gozalov A, Olesen J, Bendtsen L. Trigeminal neuralgia—a prospective systematic study of clinical characteristics in 158 patients. *Headache* 2014; **54**: 1574–82
- Zakrzewska JM, Wu J, Mon-Williams M, Phillips N, Pavitt SH. Evaluating the impact of trigeminal neuralgia. *Pain* 2017; **158**: 1166–74
- Tolle T, Dukes E, Sadosky A. Patient burden of trigeminal neuralgia: results from a cross-sectional survey of health state impairment and treatment patterns in six European countries. *Pain Pract* 2006; **6**: 153–60
- Cruccu G, Gronseth G, Alksne J, et al. AAN-EFNS guidelines on trigeminal neuralgia management. *Eur J Neurol* 2008; **15**: 1013–28
- Zakrzewska JM, Wu N, Lee JYK, Werneburg B, Hoffman D, Liu Y. Characterizing treatment utilization patterns for trigeminal neuralgia in the United States. *Clin J Pain* 2018; **34**: 691–9
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009; **6**, e1000097
- Merskey H, Bogduk N. *Classification of chronic pain. Descriptors of chronic pain syndromes and definitions of pain terms*. 2nd Edn. Seattle: IASP Press; 1994
- Gross RA, Johnston KC. Levels of evidence: taking neurology to the next level. *Neurology* 2009; **72**: 8–10
- Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011; **343**: d5928
- Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: clinical practice guidelines. *BMJ* 2016; **353**: i2089
- Spaziant R, Cappabianca P, Saini M, Peca C, Mariniello G, de Divitiis E. Treatment of trigeminal neuralgia by ophthalmic anesthetic. *J Neurosurg* 1992; **77**: 159–60
- Zavon MR, Fichte CM. Trigeminal neuralgia relieved by ophthalmic anesthetic. *JAMA* 1991; **265**: 2807
- Kondziolka D, Lemley T, Kestle JR, Lunsford LD, Fromm GH, Jannetta PJ. The effect of single-application topical ophthalmic anesthesia in patients with trigeminal neuralgia. A randomized double-blind placebo-controlled trial. *J Neurosurg* 1994; **80**: 993–7
- Kanai A, Suzuki A, Kobayashi M, Hoka S. Intranasal lidocaine 8% spray for second-division trigeminal neuralgia. *Br J Anaesth* 2006; **97**: 559–63
- Niki Y, Kanai A, Hoshi K, Okamoto H. Immediate analgesic effect of 8% lidocaine applied to the oral mucosa in patients with trigeminal neuralgia. *Pain Med* 2014; **15**: 826–31
- Galer BS, Miller KV, Rowbotham MC. Response to intravenous lidocaine infusion differs based on clinical diagnosis and site of nervous system injury. *Neurology* 1993; **43**: 1233–5
- Chaudhry P, Friedman DI. Intravenous lidocaine treatment in classical trigeminal neuralgia with concomitant persistent facial pain. *Headache* 2014; **54**: 1376–9
- Stavropoulou E, Argyra E, Zis P, Vadalouca A, Siafaka I. The effect of intravenous lidocaine on trigeminal neuralgia: a randomized double blind placebo controlled trial. *ISRN Pain* 2014; **2014**: 853826
- Baykal M, Kaplan M. Effects of oral carbamazepine with 2% lidocaine on maxillary and mandibular nerve blocks in trigeminal neuralgia. *Duzce Med J* 2010; **12**: 19–23
- Soleimanpour H, Aghamohammadi D, Ghaffarzad A, Golzari SE, Safari S, Soleimanpour M. Novel treatment in refractory tic douloureux. *J Clin Anesth* 2014; **26**: 495–6
- Arai YC, Hatakeyama N, Nishihara M, Ikeuchi M, Kurisuno M, Ikemoto T. Intravenous lidocaine and magnesium for management of intractable trigeminal neuralgia: a case series of nine patients. *J Anesth* 2013; **27**: 960–2
- Tate R, Rubin LM, Krajewski KC. Treatment of refractory trigeminal neuralgia with intravenous phenytoin. *Am J Health Syst Pharm* 2011; **68**: 2059–61
- Vargas A, Thomas K. Intravenous fosphenytoin for acute exacerbation of trigeminal neuralgia: case report and literature review. *Ther Adv Neurol Disord* 2015; **8**: 187–8
- Cheshire WP. Fosphenytoin: an intravenous option for the management of acute trigeminal neuralgia crisis. *J Pain Symptom Manage* 2001; **21**: 506–10
- Kanai A, Saito M, Hoka S. Subcutaneous sumatriptan for refractory trigeminal neuralgia. *Headache* 2006; **46**: 577–82
- Kanai A, Saito M, Hoka S. Subcutaneous sumatriptan for refractory trigeminal neuralgia. *Headache* 2006; **46**: 577–82. discussion 583–74
- Kanai A, Suzuki A, Osawa S, Hoka S. Sumatriptan alleviates pain in patients with trigeminal neuralgia. *Clin J Pain* 2006; **22**: 677–80
- Shimohata K, Shimohata T, Motegi R, Miyashita K. Nasal sumatriptan as adjunctive therapy for idiopathic trigeminal neuralgia: report of three cases. *Headache* 2009; **49**: 768–70
- Zuniga C, Diaz S, Piedimonte F, Micheli F. Beneficial effects of botulinum toxin type A in trigeminal neuralgia. *Arq Neuropsiquiatr* 2008; **66**: 500–3
- Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. *Clin Neuropharmacol* 2013; **36**: 146–50
- Devor M, Amir R, Rappaport ZH. Pathophysiology of trigeminal neuralgia: the ignition hypothesis. *Clin J Pain* 2002; **18**: 4–13

37. Woolf CJ, Wiesenfeld-Hallin Z. The systemic administration of local anaesthetics produces a selective depression of C-afferent fibre evoked activity in the spinal cord. *Pain* 1985; **23**: 361–74
38. Nagy I, Woolf CJ. Lignocaine selectively reduces C fibre-evoked neuronal activity in rat spinal cord in vitro by decreasing N-methyl-D-aspartate and neurokinin receptor-mediated post-synaptic depolarizations; implications for the development of novel centrally acting analgesics. *Pain* 1996; **64**: 59–70
39. Challapalli V, Tremont-Lukats IW, McNicol ED, Lau J, Carr DB. Systemic administration of local anesthetic agents to relieve neuropathic pain. *Cochrane Database Syst Rev* 2005; **4**: Cd003345
40. VanDenKerkhof EG, Stitt L, Clark AJ, et al. Sensitivity of the DN4 in screening for neuropathic pain syndromes. *Clin J Pain* 2017
41. Matharu MS, Cohen AS, Goadsby PJ. SUNCT syndrome responsive to intravenous lidocaine. *Cephalalgia* 2004; **24**: 985–92
42. Dergin G, Gocmen G, Sener BC. Treatment of trigeminal neuralgia with bupivacaine HCL using a temporary epidural catheter and pain pump: preliminary study. *J Craniomaxillofac Surg* 2012; **40**: 124–8
43. Lemos L, Flores S, Oliveira P, Almeida A. Gabapentin supplemented with ropivacain block of trigger points improves pain control and quality of life in trigeminal neuralgia patients when compared with gabapentin alone. *Clin J Pain* 2008; **24**: 64–75
44. Stajcic Z, Juniper RP, Todorovic L. Peripheral streptomycin/lidocaine injections versus lidocaine alone in the treatment of idiopathic trigeminal neuralgia. A double blind controlled trial. *J Craniomaxillofac Surg* 1990; **18**: 243–6
45. Bittar GT, Graff-Radford SB. The effects of streptomycin/lidocaine block on trigeminal neuralgia: a double blind crossover placebo controlled study. *Headache* 1993; **33**: 155–60
46. Han KR, Kim C, Chae YJ, Kim DW. Efficacy and safety of high concentration lidocaine for trigeminal nerve block in patients with trigeminal neuralgia. *Int J Clin Pract* 2008; **62**: 248–54
47. Goto F, Ishizaki K, Yoshikawa D, Obata H, Arie H, Terada M. The long lasting effects of peripheral nerve blocks for trigeminal neuralgia using high concentration of tetracaine dissolved in bupivacaine. *Pain* 1999; **79**: 101–3
48. Radwan IA, Saito S, Goto F. High-concentration tetracaine for the management of trigeminal neuralgia: quantitative assessment of sensory function after peripheral nerve block. *Clin J Pain* 2001; **17**: 323–6
49. Woolf CJ, Thompson SW. The induction and maintenance of central sensitization is dependent on N-methyl-D-aspartic acid receptor activation; implications for the treatment of post-injury pain hypersensitivity states. *Pain* 1991; **44**: 293–9
50. Yousef AA, Al-deeb AE. A double-blinded randomised controlled study of the value of sequential intravenous and oral magnesium therapy in patients with chronic low back pain with a neuropathic component. *Anaesthesia* 2013; **68**: 260–6
51. Brill S, Sedgwick PM, Hamann W, Di Vadi PP. Efficacy of intravenous magnesium in neuropathic pain. *Br J Anaesth* 2002; **89**: 711–4
52. Mathisen LC, Skjelbred P, Skoglund LA, Oye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. *Pain* 1995; **61**: 215–20
53. Gilron I, Booher SL, Rowan MS, Smoller MS, Max MB. A randomized, controlled trial of high-dose dextromethorphan in facial neuralgias. *Neurology* 2000; **55**: 964–71
54. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. *Clin J Pain* 2002; **18**: 22–7
55. Cranford RE, Leppik IE, Patrick B, Anderson CB, Kostick B. Intravenous phenytoin: clinical and pharmacokinetic aspects. *Neurology* 1978; **28**(9 Pt 1): 874–80
56. Boucher BA. Fosphenytoin: a novel phenytoin prodrug. *Pharmacotherapy* 1996; **16**: 777–91
57. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. *Eur Neurol* 1991; **31**: 291–4
58. Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. *Cochrane Database Syst Rev* 2014; **5**: Cd009108
59. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. *Ann Neurol* 1988; **23**: 193–6
60. Goadsby PJ. Trigeminal autonomic cephalalgias. Pathophysiology and classification. *Rev Neurol* 2005; **161**: 692–5
61. Limmroth V, Katsarava Z, Liedert B, et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. *Pain* 2001; **92**: 101–6
62. (2012) NifHaCE. Botulinum toxin type A for the prevention of headaches in adults with chronic migraine. NICE Technology appraisal guidance [TA260].
63. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2016; **86**: 1818–26
64. Castillo-Alvarez F, Hernando de la Barcena I, Marzo-Sola ME. Botulinum toxin in trigeminal neuralgia. *Medicina Clinica* 2017; **148**: 28–32
65. Aoki KR, Francis J. Updates on the antinociceptive mechanism hypothesis of botulinum toxin A. *Parkinsonism Related Disord* 2011; **17**: S28–33
66. Zakrzewska JM. Differential diagnosis of facial pain and guidelines for management. *Br J Anaesth* 2013; **111**: 95–104
67. Zakrzewska JM, Linskey ME. Trigeminal neuralgia. *BMJ* 2014; **348**: g474